Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

interests may no longer coincide. In such circumstances, the Group may be unable to continue to develop or market its products as planned and could be required to abandon or divest a product line.

In the event of breakdown, failure or breach of security on any of the Group's IT systems, the Group may be unable to maintain its business operations

The Group operates several complex information systems upon which it is dependent. The Group has back-up procedures and disaster recovery plans in place to enable the business to continue its normal operations and to mitigate any loss in the event of a failure. However, in the event of breakdown, failure or breach of security of any of these systems or the associated suppliers, the Group may be unable to maintain its business operations.

This could lead to loss of revenue and delay in product development. In addition, the Group is in the process of installing enterprise-wide information systems in its operations throughout the world. Any failure in the operation of these systems could have an adverse effect on the Group's business operations.

The Group may incur unexpected expenditure in order to comply with US environmental laws

The Group's manufacturing sites are situated in the US and are subject to national, state and local environmental laws. Compliance with environmental laws requires ongoing expenditure and any spillage or contamination found to be caused by the Group may result in clean up costs and financial penalties for the Group which could adversely affect the Group's revenues, financial condition and results of operations.

Contracts are used in all areas of operation of the business. They may contain provisions that do not protect the Group's position or with which it cannot comply

Contracts form the basis of agreement in many key activities such as mergers and acquisitions, arrangements wit
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)...  Now available is a stem cell therapy that ... , located in Guadalajara, Mexico , ... new health option: stem cell therapies for sports ... suffer from joint and muscle injuries due to professional ... rotator cuff, tennis elbow, and knee injuries. Throughout life ...
(Date:7/24/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... Results Observed in CLL Patients Treated With Low ... or Synergistic in Combination with Established TherapeuticsPreclinical Mechanism ... Compared With Other TherapeuticsSEATTLE, May 14 Trubion ... today the acceptance of three data presentations on ...
... LAB TEST NOW(R), the first retail direct-access lab testing ... Atherotech, Inc., a Birmingham, Alabama-based CLIA-laboratory to provide the ... price. The VAP Cholesterol Test is an expanded cholesterol ... risk and is the first cholesterol test to directly ...
... 1 safety studies, and plans for Phase 2 studies ... to be presentedCINCINNATI, May 14 Ausio Pharmaceuticals, LLC, ... aging global population, will lead off the Bio(R) Business ... 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, ...
Cached Biology Technology:Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 2Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 3Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 4Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 5Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting 6VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 2VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 3Ausio Pharmaceuticals to Present at Bio(R) 2009 2
(Date:7/25/2014)... this false-color image from the Terra satellite show the different ... wildfires in Eastern Russia. The burn scars show up ... The wildfires have broken across the remote parts of Eastern ... image from the MODIS instrument, it is still possible ... Two recent image features noted below show the devastating number ...
(Date:7/25/2014)... WA Nearly 600 scientists from 25 countries ... Genetics Meeting organized by the Genetics Society of ... Washington in Seattle. The conference will feature close ... research results on topics including gene expression and ... emerging technologies, evolution, aging, and a variety of ...
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... Many students have difficulty understanding and explaining how ... teach the subject, researchers at Michigan State University ... from the molecular changes underlying an evolving characteristic ... The researchers, Peter J. T. White, Merle K. ...
... Parasites comprise a large proportion of the diversity of ... included in analyses or models of food webs. If ... however, their inclusion could fundamentally alter our understanding of ... PLOS Biology this week, Santa Fe Institute ...
... Titanic sailed through just over 100 years ago was very ... is increasing ocean temperatures and harming marine food webs. Nitrogen ... international research team has now completed the first global study ... chemistry, the nitrogen cycle, at the end of the last ...
Cached Biology News:Teaching complete evolutionary stories increases learning 2Does including parasites upset food web theory? Yes and no, says new paper 2Study of oceans' past raises worries about their future 2
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
WD-repeat protein 4...
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
...
Biology Products: